Editorial: proactive anti-TNF drug monitoring in IBD-Ready for the prime time? Authors' reply
Aliment Pharmacol Ther
.
2023 Jun;57(12):1455-1456.
doi: 10.1111/apt.17339.
Authors
Sonika Sethi
1
,
Aditi Kumar
2
,
Shiluka Dias
3
,
Jonathan Blackwell
4
,
Matthew J Brookes
2
5
,
Jonathan P Segal
6
Affiliations
1
Department of Gastroenterology, Sandwell and West Birmingham NHS Trust, Birmingham, West Midlands, UK.
2
Department of Gastroenterology, The Royal Wolverhampton NHS Trust, Wolverhampton, UK.
3
Department of Gastroenterology, Guys and St Thomas' NHS Trust, London, UK.
4
Department of Gastroenterology, Croydon Healthcare NHS Trust, London, UK.
5
Research Institute in Healthcare Sciences, University of Wolverhampton, Wolverhampton, UK.
6
Department of Gastroenterology, University of Melbourne, Melbourne, Australia.
PMID:
37243471
DOI:
10.1111/apt.17339
No abstract available
Publication types
Editorial
Comment
MeSH terms
Drug Monitoring
Humans
Inflammatory Bowel Diseases* / drug therapy
Tumor Necrosis Factor Inhibitors*
Substances
Tumor Necrosis Factor Inhibitors